An artificial intelligence-based model for prediction of clonal hematopoiesis variants in cell-free DNA samples
Circulating tumor DNA is a critical biomarker in cancer diagnostics, but its accurate interpretation requires careful consideration of clonal hematopoiesis (CH), which can contribute to variants in cell-free DNA and potentially obscure true tumor-derived signals. Accurate detection of somatic variants of CH origin in plasma samples remains challenging in the absence of matched white blood cells sequencing. Here we present an open-source machine learning framework (MetaCH) which classifies variants in cfDNA from plasma-only samples as CH or tumor origin, surpassing state-of-the-art classification rates.
Authors
- Zhongwu Lai (ORCID: https://orcid.org/0000-0002-1506-8222)
- Gerald J. Sun (ORCID: https://orcid.org/0000-0002-1646-3590)
- J. Carl Barrett (ORCID: https://orcid.org/0000-0003-4042-9859)
- Etai Jacob (ORCID: https://orcid.org/0009-0007-4599-0457)
- Marzieh Haghighi
- Elizabeth Choe
- Aleksandra Markovets
- Gustavo Arango-Argoty
Institutions
- AstraZeneca (United States) (US)
Publication Details
- Journal
- npj Precision Oncology
- Published
- 2025-05-20
- DOI
- https://doi.org/10.1038/s41698-025-00921-w
- Citations
- 3
- Primary Topic
- Cancer Genomics and Diagnostics
- Type
- article
- Field-Weighted Citation Impact
- 2.81
Funders
- AstraZeneca